RESEARCH INVENTION JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 5(2):97-100, 2025

©RIJSES Publications

ONLINE ISSN: 1115-618X

PRINT ISSN: 1597-2917

https://doi.org/10.59298/RIJSES/2025/5297100

The Role of Gut Microbiota Modulation through Fecal Microbiota Transplantation (FMT) in Managing Type 1 Diabetes: A Scoping Review

Ngugi Mwaura J.

School of Natural and Applied Sciences Kampala International University Uganda

ABSTRACT

Type 1 diabetes (T1D) is a chronic autoimmune disorder characterized by the destruction of insulin-producing beta cells, necessitating innovative therapeutic strategies beyond conventional insulin therapy. Emerging evidence highlights the role of gut microbiota dysbiosis in T1D pathogenesis, with fecal microbiota transplantation (FMT) emerging as a promising intervention to restore microbial balance and modulate immune and metabolic responses. This scoping review synthesized current knowledge on the role of FMT in managing T1D, focusing on its mechanisms of action, preclinical and clinical evidence, and future directions. Preclinical studies in animal models, such as non-obese diabetic (NOD) mice, have demonstrated that FMT delays diabetes onset and improves glucose tolerance. Early-phase clinical trials and case reports in humans have shown that FMT can reduce systemic inflammation and improve glycemic control, though its effects on beta-cell function remain modest. Challenges such as microbiome heterogeneity, safety concerns, and the need for standardized protocols must be addressed to optimize FMT's therapeutic potential. This review employed a scoping methodology, systematically analyzing preclinical and clinical studies to evaluate FMT's efficacy and safety in T1D. Future research should focus on personalized FMT approaches, integration with probiotics and immune-based therapies, and long-term outcomes to establish FMT as a viable strategy for T1D management. By addressing these challenges, FMT holds promise for improving the lives of individuals with T1D and advancing toward sustainable disease management.

Keywords: Fecal microbiota transplantation, type 1 diabetes, gut microbiota, immune modulation, SCFAs.

INTRODUCTION

Type 1 diabetes (T1D) is a chronic autoimmune disorder characterized by the destruction of insulin-producing beta cells in the pancreas, leading to lifelong dependence on exogenous insulin therapy [1–3]. Despite advances in insulin delivery systems and glucose monitoring technologies, managing T1D remains challenging, with patients facing significant risks of acute and long-term complications, including hypoglycemia, diabetic ketoacidosis, and microvascular and macrovascular diseases. The pathogenesis of T1D involves a complex interplay of genetic predisposition, environmental triggers, and immune dysregulation, with growing evidence implicating gut microbiota as a key modulator of immune responses and metabolic health [4, 5].

The gut microbiota, a diverse community of microorganisms residing in the gastrointestinal tract, plays a critical role in maintaining immune homeostasis, regulating metabolism, and protecting against pathogenic infections [6]. Dysbiosis, or an imbalance in the gut microbial composition, has been observed in individuals with T1D and is thought to contribute to the breakdown of immune tolerance and the progression of autoimmunity [7]. Recent studies have highlighted the potential of gut microbiota modulation as a therapeutic strategy for T1D, with fecal microbiota transplantation (FMT) emerging as a promising intervention. FMT involves the transfer of fecal material from a healthy donor to a recipient, aiming to restore a balanced and functional gut microbiome.

This scoping review explores the role of FMT in managing T1D, focusing on its mechanisms of action, preclinical and clinical evidence, and potential challenges. By synthesizing current knowledge, this review aims to provide a comprehensive understanding of the therapeutic potential of FMT in T1D and identify future research directions to optimize its application.

Mechanisms of Action of FMT in Type 1 Diabetes

The gut microbiota influences systemic immune responses and metabolic processes through multiple mechanisms, making it a potential target for T1D management [6, 7]. FMT can modulate the gut microbiome by introducing a diverse and stable microbial community, which can outcompete pathogenic species, restore barrier integrity, and regulate immune function. One of the key mechanisms by which FMT may benefit individuals with T1D is through the restoration of immune homeostasis. The transplanted microbiota can promote the expansion of regulatory T cells (Tregs) and the production of anti-inflammatory cytokines, such as interleukin-10 (IL-10), while suppressing pro-inflammatory responses. This immunomodulatory effect may help mitigate the autoimmune destruction of pancreatic beta cells.

Another important mechanism is the production of microbial metabolites, such as short-chain fatty acids (SCFAs), which have been shown to enhance insulin sensitivity, reduce inflammation, and promote beta-cell survival [8]. SCFAs, including acetate, propionate, and butyrate, are produced through the fermentation of dietary fibers by gut bacteria and play a critical role in maintaining metabolic health. FMT can increase the abundance of SCFA-producing bacteria, thereby improving metabolic outcomes in individuals with T1D. Additionally, FMT may enhance gut barrier function, reducing the translocation of microbial products, such as lipopolysaccharide (LPS), into systemic circulation, which can trigger chronic inflammation and insulin resistance.

Preclinical Evidence: Insights from Animal Models

Preclinical studies in animal models have provided valuable insights into the potential of FMT to modulate T1D progression [9, 10]. Non-obese diabetic (NOD) mice, a widely used model of T1D, have been instrumental in evaluating the effects of gut microbiota modulation on autoimmune diabetes. Studies have shown that FMT from healthy donors can delay the onset of diabetes and reduce its incidence in NOD mice. These protective effects are associated with increased microbial diversity, enhanced SCFA production, and the induction of Tregs.

In addition to NOD mice, other animal models, such as streptozotocin (STZ)-induced diabetic mice, have been used to investigate the metabolic benefits of FMT [11, 12]. FMT has been shown to improve glucose tolerance, increase insulin sensitivity, and reduce pancreatic inflammation in these models. Furthermore, FMT can modulate the gut-brain axis, influencing neuroendocrine pathways that regulate glucose metabolism and appetite. These preclinical findings highlight the potential of FMT to address both the autoimmune and metabolic aspects of T1D, providing a strong rationale for clinical investigations.

Clinical Evidence: Early-Phase Trials and Case Studies

The clinical application of FMT in T1D is still in its early stages, with a limited number of studies conducted to date. Early-phase trials and case reports have primarily focused on assessing the safety and feasibility of FMT in individuals with T1D, with secondary outcomes including changes in gut microbiome composition, immune markers, and metabolic parameters. One of the pioneering studies evaluated the effects of FMT in children with newly diagnosed T1D, demonstrating that FMT could increase microbial diversity and reduce markers of systemic inflammation [13, 14]. However, the effects on beta-cell function and insulin requirements were modest, highlighting the need for further optimization of FMT protocols.

Another study explored the impact of FMT on glycemic control in adults with T1D, showing improvements in postprandial glucose levels and insulin sensitivity. These metabolic benefits were associated with increased abundance of SCFA-producing bacteria and enhanced gut barrier function. Case reports have also documented the potential of FMT to induce remission of autoimmune diabetes in individuals with concurrent conditions, such as inflammatory bowel disease (IBD). While these findings are promising, larger and more rigorous clinical trials are needed to establish the efficacy and long-term safety of FMT in T1D.

Challenges and Future Directions

Despite the promising preclinical and early clinical evidence, several challenges must be addressed to realize the full potential of FMT in managing T1D. One of the primary challenges is the heterogeneity of gut microbiome composition among individuals, which may influence the response to FMT [15, 16]. Personalized approaches, tailored to the unique microbial and immunological profiles of individual patients, may enhance the efficacy of FMT. Additionally, the optimal timing, frequency, and route of FMT administration in T1D require further investigation.

Another challenge is the potential for adverse effects, such as the transmission of infectious agents, the induction of immune reactions, and the long-term stability of the transplanted microbiota. Rigorous donor screening, standardized processing protocols, and close monitoring of recipients are essential to mitigate these risks. Furthermore, the integration of FMT with other therapeutic modalities, such as probiotics, prebiotics, and immune-based therapies, may enhance its effects and provide a more comprehensive approach to T1D management [17, 18].

Future research should focus on optimizing FMT protocols, evaluating long-term efficacy and safety, and assessing the impact of FMT on beta-cell function and autoimmune responses. The inclusion of diverse patient populations, including children, adults, and individuals with varying disease durations, is essential to ensure equitable access to this innovative therapy. Advances in microbiome sequencing and metabolomics will provide deeper insights into the mechanisms underlying FMT and guide the development of next-generation microbiome-based therapies.

CONCLUSION

Fecal microbiota transplantation represents a promising therapeutic strategy for managing type 1 diabetes, offering the potential to restore immune homeostasis, improve metabolic outcomes, and enhance gut barrier function. Preclinical studies in animal models have demonstrated the efficacy of FMT in delaying diabetes onset and improving glucose tolerance, while early-phase clinical trials have shown promising results in reducing inflammation and improving glycemic control. However, significant challenges remain, including the heterogeneity of gut microbiome composition, the need for standardized protocols, and the potential for adverse effects. Addressing these challenges will require continued innovation in FMT technology, personalized approaches, and the integration of FMT with other therapeutic modalities. As research progresses, FMT and other microbiome-based therapies hold great promise for improving the health and quality of life of individuals with T1D. By leveraging the unique strengths of FMT and addressing its limitations, we can move closer to achieving the goal of effective and sustainable T1D management, bringing hope to patients and their families.

REFERENCES

1. Obeagu, E.I., Okechukwu, U., Alum, E.U.: Poor Glycaemic Control among Diabetic Patients: A Review on Associated Factors. (2023)
2. Alum, E.U., Ugwu, O.P.C., Obeagu, E.I.: Beyond Pregnancy: Understanding the Long-Term Implications of Gestational Diabetes Mellitus. INOSR Scientific Research. 11, 63–71 (2024). https://doi.org/10.59298/INOSRSR/2024/1.1.16371
3. Alum, E.U., Okechukwu, U., Obeagu, E.I., Aja, P.M.: Nutritional Care in Diabetes Mellitus: A Comprehensive Guide. https://doi.org/10.58538/IJIAR/2057
4. Dedrick, S., Sundaresh, B., Huang, Q., Brady, C., Yoo, T., Cronin, C., Rudnicki, C., Flood, M., Momeni, B., Ludvigsson, J., Altindis, E.: The Role of Gut Microbiota and Environmental Factors in Type 1 Diabetes Pathogenesis. Front Endocrinol (Lausanne). 11, 513621 (2020). https://doi.org/10.3389/FENDO.2020.00078/PDF
5. Del Chierico, F., Rapini, N., Deodati, A., Matteoli, M.C., Cianfarani, S., Putignani, L.: Pathophysiology of Type 1 Diabetes and Gut Microbiota Role. International Journal of Molecular Sciences 2022, Vol. 23, Page 14650. 23, 14650 (2022). https://doi.org/10.3390/IJMS232314650
6. Ugwu, O. P. C., Alum, E. U., Okon, M. B., Obeagu, E. I. Mechanisms of microbiota modulation: Implications for health, disease, and therapeutic interventions. Medicine (Baltimore). 2024 May 10;103(19):e38088. doi: 10.1097/MD.0000000000038088.
7. Morris, G., Berk, M., Carvalho, A., Caso, J., Sanz, Y., Maes, M.: The Role of Microbiota and Intestinal Permeability in the Pathophysiology of Autoimmune and Neuroimmune Processes with an Emphasis on Inflammatory Bowel Disease Type 1 Diabetes and Chronic Fatigue Syndrome. Curr Pharm Des. 22, 6058–6075 (2016). https://doi.org/10.2174/1381612822666160914182822/CITE/REFWORKS
8. Yao, Y., Cai, X., Fei, W., Ye, Y., Zhao, M., Zheng, C.: The role of short-chain fatty acids in immunity, inflammation and metabolism. Crit Rev Food Sci Nutr. 62, 1–12 (2022). https://doi.org/10.1080/10408398.2020.1854675
9. Zhang, S., Deng, F., Chen, J., Chen, F., Wu, Z., Li, L., Hou, K.: Fecal microbiota transplantation treatment of autoimmune-mediated type 1 diabetes: A systematic review. Front Cell Infect Microbiol. 12, 1075201 (2022). https://doi.org/10.3389/FCIMB.2022.1075201/PDF
10. Blok, L., Hanssen, N., Nieuwdorp, M., Rampanelli, E.: From Microbes to Metabolites: Advances in Gut Microbiome Research in Type 1 Diabetes. Metabolites 2025, Vol. 15, Page 138. 15, 138 (2025). https://doi.org/10.3390/METABO15020138
11. Ren, X., Zhang, F., Zhang, M., Fang, Y., Chen, Z., Huan, M.: Fecal microbiota transplantation: whole grain highland barley improves glucose metabolism by changing gut microbiota. Food Science and Human Wellness. 13, 2014–2024 (2024). https://doi.org/10.26599/FSHW.2022.9250167
12. Wang, Y., Ni, Z., Li, J., Shao, Y., Yong, Y., Lv, W., Zhang, S., Fu, T., Chen, A.: Cordyceps cicadae polysaccharides alleviate hyperglycemia by regulating gut microbiota and its mmetabolites in high-fat diet/streptozocin-induced diabetic mice. Front Nutr. 10, 1203430 (2023). https://doi.org/10.3389/FNUT.2023.1203430/BIBTEX
13. Miyauchi, E., Shimokawa, C., Steimle, A., Desai, M.S., Ohno, H.: The impact of the gut microbiome on extra-intestinal autoimmune diseases. Nature Reviews Immunology 2022 23:1. 23, 9–23 (2022). https://doi.org/10.1038/s41577-022-00727-y
14. Zhang, T., Gao, G., Sakandar, H.A., Kwok, L.Y., Sun, Z.: Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target. Front Nutr. 9, 814269 (2022). https://doi.org/10.3389/FNUT.2022.814269/PDF

15. Alum, E.U. Optimizing patient education for sustainable self-management in type 2 diabetes. *Discov Public Health* **22**, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
16. Li, N., Zuo, B., Huang, S., Zeng, B., Han, D., Li, T., Liu, T., Wu, Z., Wei, H., Zhao, J., Wang, J.: Spatial heterogeneity of bacterial colonization across different gut segments following inter-species microbiota transplantation. Microbiome. 8, 1–24 (2020). https://doi.org/10.1186/S40168-020-00917-7/FIGURES/10
17. Deligiorgi, M. V., Trafalis, D.T.: A Concerted Vision to Advance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint Inhibitors. International Journal of Molecular Sciences 2023, Vol. 24, Page 7630. 24, 7630 (2023). https://doi.org/10.3390/IJMS24087630
18. Jain, T., Sharma, P., Are, A.C., Vickers, S.M., Dudeja, V.: New Insights Into the Cancer–Microbiome–Immune Axis: Decrypting a Decade of Discoveries. Front Immunol. 12, 622064 (2021). https://doi.org/10.3389/FIMMU.2021.622064/PDF

CITE AS: Ngugi Mwaura J. (2025). The Role of Gut Microbiota Modulation through Fecal Microbiota Transplantation (FMT) in Managing Type 1 Diabetes: A Scoping Review. RESEARCH INVENTION JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 5(2):97-100.
https://doi.org/10.59298/RIJSES/2025/5297100